# Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

> **NCT04361825** · PHASE2 · COMPLETED · sponsor: **Se-Hoon Lee** · enrollment: 42 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04361825
- **Lead sponsor:** Se-Hoon Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2023-10-25
- **Final completion:** 2023-10-25
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361825, "Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04361825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*